SCHEMBL24253924

SCHEMBL24253924

O=C1CCCC2(CCN(c3cc(=O)n(Cc4ccccc4)nc3OC3CCOCC3)CC2)N1c1ccc(F)c(F)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 7/20 0.36
MAPT P10636 6/20 0.36
ALDH1A1 P00352 6/20 0.36
MEN1 O00255 5/20 0.36
KMT2A Q03164 5/20 0.36
LMNA P02545 4/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
GLA P06280 1/20 0.36
HTT P42858 5/20 0.36
HCRTR1 O43613 1/20 0.33
HCRTR2 O43614 1/20 0.33
KCNH2 Q12809 1/20 0.33
LTC4S Q16873 1/20 0.33
TP53 P04637 1/20 0.32
S1PR3 Q99500 1/20 0.32
RIPK1 Q13546 1/20 0.31
KDM4E B2RXH2 2/20 0.31
GAA P10253 2/20 0.31
POLB P06746 1/20 0.31
HSP90AA1 P07900 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24253519 0.87 HCRTR1 (0.33) MAPTALDH1A1MEN1KMT2AHCRTR1
SCHEMBL24253606 0.77 HCRTR1 (0.38) NPSR1MAPTALDH1A1MEN1KMT2A
SCHEMBL30423647 0.77 EP300 (0.34) KCNH2
SCHEMBL24253855 0.77 EP300 (0.34) KCNH2
SCHEMBL30423965 0.76 EP300 (0.32) MAPTALDH1A1LMNAGAAALOX15
SCHEMBL24253508 0.76 EP300 (0.32) MAPTALDH1A1LMNAGAAALOX15
SCHEMBL30494667 0.76 HCRTR1 (0.37) NPSR1MAPTALDH1A1MEN1KMT2A
SCHEMBL24253950 0.74 GPR119 (0.36) CYP2C19
SCHEMBL26307796 0.74 HCRTR1 (0.38) NPSR1MAPTALDH1A1MEN1KMT2A
SCHEMBL24253951 0.73 PDE10A (0.37) MAPTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
EP-4196478-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF Novartis AG (CH) 2023-06-21 EP disclosed
CN-116157404-A Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof 诺华股份有限公司 2023-05-23 CN disclosed
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof REN, NR3C2, PKD1 NPSR1 191/4885MAPT 4450/4885ALDH1A1 323/4885
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF REN, NR3C2, PKD1 NPSR1 191/4885MAPT 4450/4885ALDH1A1 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.